Medicine
Zelapar 1.25 mg orally disintegrating tablet
Zelapar 1.25 mg orally disintegrating tablet is a prescription medicine containing Selegiline for oral use, marketed by Bausch Health, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature, 25°C (77°F), excursions permitted to…
Key facts
- Active ingredient (INN)
- Selegiline
- Brand
- Zelapar
- Strength
- 1.25 mg
- Dosage form
- Orally disintegrating tablet
- Route
- Oral
- Packs
- 6 pouches
- Marketing authorisation holder
- Bausch Health
- Manufacturer
- Bausch Health
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature, 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store blister tablets in sachet pouch at all times.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N04BD01 Selegiline
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 June 2006
- Identifiers
- RxCUI 859190, 859192DailyMed set ID 380d7717-2a79-42f3-a712-efe5e7696ba0NDC 0187-0453Application NDA021479
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 pouch in 1 carton / 10 tablet, orally disintegrating in 1 pouch | 0187-0453-02 | Bausch Health | 14 June 2006 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 June 1989 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Selegiline
Clinical summary
Selegiline is a monoamine oxidase inhibitor indicated for the treatment of adults with major depressive disorder (MDD). It is available as capsules, tablets and transdermal patches for oral use. MedsAcross supplies Selegiline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SelegilineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EMSAM prescribing information (Viatris Specialty) · U.S. National Library of Medicine, DailyMed
Need Zelapar 1.25 mg orally disintegrating tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.